M Burnier1. Show Affiliations » 1. Division of Hypertension and Vascular Medicine, CHUV, Lausanne, Switzerland. Michel.Burnier@chuv.hospvd.ch
Abstract
Entities: Gene
Mesh: See more » Angiotensin I/metabolismAngiotensin II/metabolismAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme Inhibitors/pharmacologyAnimalsAntihypertensive Agents/pharmacokineticsAntihypertensive Agents/pharmacologyBenzimidazoles/pharmacologyBinding, CompetitiveBiphenyl Compounds/pharmacologyBlood Pressure/drug effectsDrug DesignHumansIrbesartanLosartan/pharmacologyPeptidyl-Dipeptidase A/metabolismProtein BindingReceptor, Angiotensin, Type 1Receptor, Angiotensin, Type 2Receptors, Angiotensin/classificationReceptors, Angiotensin/physiologyRenin-Angiotensin System/drug effectsSaralasin/pharmacologyTetrazoles/pharmacologyValine/analogs & derivativesValine/pharmacologyValsartan
Substances: See more » Angiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBenzimidazolesBiphenyl CompoundsReceptor, Angiotensin, Type 1Receptor, Angiotensin, Type 2Receptors, AngiotensinTetrazolesAngiotensin IIValsartanAngiotensin IPeptidyl-Dipeptidase ASaralasinValineIrbesartanLosartancandesartan cilexetil
Year: 2001 PMID: 11171802 DOI: 10.1161/01.cir.103.6.904
Source DB: PubMed Journal: Circulation ISSN: 0009-7322 Impact factor: 29.690